⏳ Fetching live dividend data...
Home › Calculator › OSMT Dividend Calculator 2026
RVL Pharmaceuticals plc · NASDAQ
Price: $1.11 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in OSMT → $2013777910596.36M in 10 years · $167,552,288,432,975,300.00/month
Osmotica Pharmaceuticals plc, headquartered in Bridgewater, New Jersey, operates as a fully integrated biopharmaceutical company. The firm's primary focus involves the development and commercialization of various pharmaceutical products, serving markets in the United States, Argentina, and Hungary. Their actively promoted product lineup includes M-72, an extended-release methylphenidate hydrochloride tablet designed to treat attention deficit hyperactivity disorder (ADHD), and Osmolex ER, an extended-release amantadine formulation used for Parkinson's disease and specific drug-induced movement disorders in adults. They also offer Upneeq, an oxymetazoline hydrochloride ophthalmic solution prescribed for blepharoptosis (drooping eyelids). In their development pipeline, Arbaclofen extended-release tablets are currently undergoing Phase III clinical trials for managing spasticity associated with multiple sclerosis, while OS870 is in Phase I trials for neurodegenerative disorders. Beyond these, Osmotica provides women's health solutions, such as Divigel for menopause management and OB Complete, a dietary supplement tailored for the prenatal, pregnancy, and postnatal periods. The company's broader portfolio also encompasses numerous non-promoted pharmaceutical products. These include methylphenidate ER tablets for ADHD, venlafaxine ER tablets addressing major depressive and social anxiety disorders, hydromorphone ER for pain relief, and nifedipine ER for hypertension. Other offerings feature sodium benzoate/sodium phenylacetate for hyperammonemia, oxybutynin ER for overactive bladder, and prescription prenatal vitamins. Additionally, their non-promoted items comprise Lorzone, an immediate-release chlorzoxazone for acute musculoskeletal pain (when combined with rest and physical therapy), ConZip (tramadol hydrochloride) for pain management, and nitrofurantoin for urinary tract infections, alongside Osmodex and various other abbreviated new drug applications.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open OSMT position with:
Real after-tax yield depends on where you live and how you hold OSMT.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 180.18% | 177.38% | $18,018 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 153.15% | 150.35% | $15,315 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 144.14% | 141.34% | $14,414 / yr |
| 🇬🇧 UK ISA | 0% | 180.18% | 177.38% | $18,018 / yr |
| 🇬🇧 UK Taxable | 8.75% | 164.41% | 161.61% | $16,441 / yr |
| 🇨🇦 TFSA | 0% | 180.18% | 177.38% | $18,018 / yr |
| 🇨🇦 CA Taxable | 25% | 135.13% | 132.33% | $13,513 / yr |
| 🇦🇺 Super (pension) | 15% | 153.15% | 150.35% | $15,315 / yr |
| 🇦🇺 AU Taxable | 30% | 126.13% | 123.33% | $12,613 / yr |
| 🇩🇪 DE Taxable | 26.375% | 132.66% | 129.86% | $13,266 / yr |
| 🇫🇷 FR Taxable | 30% | 126.13% | 123.33% | $12,613 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
OSMT pays quarterly — 4 times per year. Next ex-div: TBD.
How OSMT compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for OSMT sourced from FMP /financial-growth endpoint — real data, not estimates.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the OSMT dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
RVL Pharmaceuticals plc (OSMT) is currently trading at $1.11, trading near its 52-week low. The current dividend yield is 180.18% based on an annual payout of $2.00 per share.
RVL Pharmaceuticals plc (OSMT) is a healthcare stock currently trading at $1.11 with a dividend yield of 180.18%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →